Acromegaly Treatment Market

Acromegaly Treatment Market Size

Acromegaly Treatment Market size was valued at USD 2.2 billion in 2023 and is estimated to grow at 5.4% CAGR from 2024 to 2032, due to the rising prevalence and incidence of acromegaly and pituitary tumors coupled with growing global awareness of the disease.

According to Orphanet, the global prevalence of acromegaly ranges from 1 in 7,500 to 1 in 35,800 people, while the annual incidence is between 1 in 91,000 to 1 in 526,000 people. Thus, the prevalence of acromegaly has significantly boosted the demand for effective treatments, thereby driving market growth. Furthermore, the rising demand for advanced treatments is encouraging pharmaceutical companies to invest in research and development (R&D). These efforts focus on creating innovative therapies and delivery methods for rare disease treatment, thereby exposing new market opportunities.

Acromegaly is a rare hormonal disorder resulting from excess growth hormone secretion, typically due to a benign pituitary adenoma. Treatment aims to reduce growth hormone levels, alleviate symptoms, and prevent complications. Primary treatments include surgical resection of the pituitary tumor, often achieved via transsphenoidal surgery. Medications such as somatostatin analogs, and growth hormone receptor antagonists are used to inhibit growth hormone production or block its effects. Radiotherapy is also an option for patients who do not respond adequately to surgery or medication.

Acromegaly Treatment Market Trends

Expanding R&D activities are driving the market growth by initiating a robust pipeline of innovative therapies. Pharmaceutical companies are heavily investing in the discovery and development of novel treatment options, including advanced drugs and improved delivery methods to address the burden of rare diseases including acromegaly.

• For instance, in June 2024, Crinetics Pharmaceuticals, Inc. presented findings from its clinical development program for oral, once-daily investigational paltusotine in acromegaly. The data included results from the Phase 3 PATHFNDR-2 trial, a new analysis of patient-reported outcome (PRO) data from the Phase 3 PATHFNDR-1 trial, and interim long-term efficacy and safety results at 42 months from the open-label ACROBAT Advance extension study. These comprehensive results highlighted paltusotine's potential as an effective and convenient treatment option for acromegaly, reinforcing its promise in ongoing clinical development. Such trials in the pipeline are expected to spur the market growth.
  

Moreover, the growing focus on emerging treatment methods, strategic approaches by key players, approvals, government support and funding are further boosting market demand.

Acromegaly Treatment Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on the type, the market is categorized into ectopic acromegaly and pseudo acromegaly. The pseudo acromegaly segment is set to lead the market, accounting for the largest revenue of USD 1.3 billion in 2023, anticipating its dominance throughout the forecast period with a CAGR of 5.3%.

• Pseudo acromegaly, characterized by acromegaly-like symptoms without elevated growth hormone levels, dominated the market due to its increasing diagnosis and recognition. This condition often stems from underlying disorders like insulin resistance or genetic mutations, necessitating specialized treatment approaches.
  
• Also, the growing awareness and advancements in diagnostic techniques have led to higher identification rates of pseudo acromegaly. Therefore, rising demand for tailored therapies along with pharmaceutical companies focusing on developing effective treatments will spur the market's expansion in this segment.

Learn more about the key segments shaping this market

Download Free PDF

Based on treatment type, the acromegaly treatment market is classified into medical therapy, surgery, and other treatment types. The medical therapy segment holds the largest market share of 45.7% in 2023 and is expected to maintain dominance throughout the analysis period.

• The segmental dominance is due to the effectiveness and convenience of pharmacological interventions compared to surgical options. The somatostatin analogs gained significant traction in the medical therapy treatment due to the wide availability and cost-efficiency of these drugs.
  
• Somatostatin analogs are highly effective and often prescribed as first-line treatments. The market growth is further driven by an increasing number of product approvals. For instance, in June 2020, Chiasma, Inc. received FDA approval for MYCAPSSA (octreotide) capsules for long-term maintenance treatment in acromegaly patients who have responded to and tolerated octreotide or lanreotide. MYCAPSSA is the first and only oral somatostatin analog approved by the FDA, utilizing Chiasma's Transient Permeability Enhancer (TPE) technology. Similarly, in June 2021, Chiasma submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Mycapssa as maintenance therapy for adults with acromegaly.
  
• Thus, a growing number of approvals, expanded research and the effectiveness of the medication solidifies the segment dominance in the market.
  

Based on age group, the acromegaly treatment market is segmented into less than 40, 41-60, and 61 above. In 2023, the 41-60 age group segment is expected to hold the highest market share, exhibiting 5.2% CAGR during the analysis period.

• This demographic is most affected by acromegaly with increasing prevalence of pituitary tumors and related complications in middle-aged individuals. Therefore, pharmaceutical companies and healthcare providers focus on addressing the specific treatment needs of this age group, thereby contributing to its market dominance.

Looking for region specific data?

Download Free PDF

The U.S. dominated the North American acromegaly treatment market accounting for USD 876.4 million in 2023 and is anticipated to show considerable growth over the analysis period.

• The U.S. holds a significant share of the North American market due to its large population and high healthcare spending. For instance, as per the National Institutes of Health (NIH) and Endocrine Society, across 13 studies on acromegaly prevalence, approximately 24,000 individuals are believed to have the condition in the U.S. Among them, around 8,000 people receive chronic treatment with somatostatin analog injections. Therefore, leading pharmaceutical and biotech companies in the U.S. are actively engaged in R&D to develop novel therapies, thereby augmenting the market growth.
  

Germany exhibited a high growth potential in the European acromegaly treatment market.

• Germany is a key player in the European acromegaly treatment market, characterized by advanced healthcare infrastructure and high healthcare expenditure.
  
• In addition, increasing R&D efforts coupled with expanded product launches are creating new opportunities in the market. For instance, in July 2021, ADVANZ PHARMA introduced MYTOLAC (lanreotide) in Germany, marking the first generic lanreotide available for treating acromegaly, grade 1 and certain grade 2 gastroenteropancreatic neuroendocrine tumors, and symptoms associated with neuroendocrine tumors.
  
• Thus, these advancements enhance treatment options that improve patient access to innovative and effective therapies, thereby driving the country level market growth.
  

The Asia Pacific acromegaly treatment market is poised for rapid growth with a CAGR of 5.9% during the forecast period.

• This expansion is driven by increasing awareness of acromegaly, improved diagnostic techniques, and the rising prevalence of the condition in the region.
  
• Also, growing healthcare expenditure, enhanced access to advanced treatments, and the presence of emerging economies such as China and India contribute significantly to regional market growth.
  
• Furthermore, investments in R&D and strategic collaborations among pharmaceutical companies further bolster the market, promising better treatment options and improved patient outcomes in the Asia Pacific region.
  

Acromegaly Treatment Market Share

The acromegaly treatment industry is characterized by several pharmaceutical companies vying for market share. Key players are dominating the market with their extensive portfolios of somatostatin analogs, growth hormone receptor antagonists, and other therapeutic options. The companies invest significantly in R&D to innovate new treatments and improve existing ones to sustain their position in the market. Additionally, strategic collaborations, mergers, and acquisitions are common tactics employed to strengthen the market presence and expand product offerings.

Acromegaly Treatment Market Companies

Few of the prominent players operating in the acromegaly treatment industry include:

• ADVANZ PHARMA
• Amryt Pharma Plc
• Chiasma, Inc
• Cipla
• Crinetics Pharmaceuticals Inc
• Dauntless Pharmaceuticals
• Eli Lilly and Company
• Ipsen SA
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
  

Acromegaly Treatment Industry News:

• In May 2024, Cipla obtained approval from the U.S, Food and Drug Administration (FDA) for its Lanreotide injection, a therapeutic equivalent generic version of Somatuline Depot Injection. The approval allowed Cipla to market Lanreotide injection in various strengths. This strategic approval enhanced company to outreach to untapped economies.
  
• In March 2024, Chiesi Global Rare Diseases, a division of the Chiesi Group, introduced Rethink Acromegaly, a disease education initiative. The platform offer latest information and resources to empower individuals living with acromegaly, caregivers, and healthcare professionals. This launch aimed to raise awareness and understanding of complex condition population.
  

The acromegaly treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Ectopic acromegaly
• Pseudo acromegaly

Market, By Treatment Type

• Medical therapy
  • Type
    • Somatostatin analogs
    • Growth hormone receptor antagonists (GHRA)
    • Dopamine agonists
    • Combination drugs
  • Route of administration      
    • Injectable
    • Oral
    • Intranasal
• Surgery
• Other treatment types

Market, By Age Group

• Less than 40
• 41-60
• 61 above

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa